Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ArriVent BioPharma, Inc.AVBP · Entity 4699 | Chief Financial Officer | February 02, 2026 | February 04, 2026 |
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Director | June 10, 2026 | June 11, 2026 |
| Janux Therapeutics, Inc.JANX · Entity 4864 | Director | June 11, 2026 | June 13, 2026 |
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | COO, CFO | May 12, 2023 | May 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ArriVent BioPharma, Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.67 · Expires 2036-02-02 | Direct | 140,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 140,000 · Balance 140,000 F1: The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
Corbus Pharmaceuticals Holdings, Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 12,140 |
Reported balance
After 2026-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-10 · Sale · Disposed 2,026 · Balance 12,140 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.
Janux Therapeutics, Inc.
Report date June 11, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,750 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,500 · Balance 11,750 F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.66 · Expires 2036-06-10 | Direct | 15,500 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 15,500 · Balance 15,500 F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.
PMV Pharmaceuticals, Inc.
Report date May 12, 2023 · Filed May 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.70 · Expires 2033-05-12 | Direct | 150,000 |
Reported balance
After 2023-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-12 · Grant · Acquired 150,000 · Balance 150,000 F1: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 13, 2026 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $13.66 | $0.00 |
DisclosureSEC source: 0001666963-26-000003 · form4-06122026_080609.xml · derivative · entry 2 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2036-06-10 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. Read SEC document |
| June 11, 2026 Filed Jun 13, 2026 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001666963-26-000003 · form4-06122026_080609.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,750 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 16:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | SaleCommon Stock, par value $0.0001 per share | 2,026 | $7.91 | $16,033.16 |
DisclosureSEC source: 0001193125-26-267672 · ownership.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,140 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported. Read SEC document |
| May 19, 2026 Filed May 21, 2026 17:07 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock options (right to buy) · Derivative | 12,300 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001193125-26-234860 · ownership.xml · derivative · entry 2 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,300 Underlying: Common Stock · 12,300 shares Expires 2026-05-19 F3 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 19, 2026 Filed May 21, 2026 17:07 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 3,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-234860 · ownership.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,166 F1 · shares: On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2 · balance_after: This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 20:41 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $22.67 | $0.00 |
DisclosureSEC source: 0001104659-26-010473 · tm265104-2_4seq1.xml · derivative · entry 1 Kung Winston · CIK 0001666963 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 23:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 11,667 | $0.00 Strike: $25.46 | $0.00 |
DisclosureSEC source: 0001415889-25-017310 · form4-06132025_070601.xml · derivative · entry 2 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,667 Underlying: Common Stock · 11,667 shares Expires 2035-06-10 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 23:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017310 · form4-06132025_070601.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 16:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock options (right to buy) · Derivative | 16,000 | $0.00 Strike: $7.42 | $0.00 |
DisclosureSEC source: 0000950170-25-080313 · ownership.xml · derivative · entry 2 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-05-30 F3 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 16:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080313 · ownership.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,366 F1 · shares: On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2 · balance_after: This amount includes 10,366 unvested RSUs subject to each grant's vesting schedule as previously reported. Read SEC document |
| February 03, 2025 Filed Feb 14, 2025 16:24 UTC | ArriVent BioPharma, Inc. AVBP · Entity 4699 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $27.56 | $0.00 |
DisclosureSEC source: 0001104659-25-014164 · tm256714-2_4seq1.xml · derivative · entry 1 Kung Winston · CIK 0001666963 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 3, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 16:48 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock options (right to buy) · Derivative | 5,566 | $0.00 Strike: $53.52 | $0.00 |
DisclosureSEC source: 0000950170-24-099175 · ownership.xml · derivative · entry 2 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,566 Underlying: Common Stock · 5,566 shares Expires 2034-08-16 F3 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 16:48 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 5,566 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-099175 · ownership.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,566 F1 · shares: On August 16, 2024, 5,566 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2 · balance_after: This amount includes 5,566 unvested RSUs that were granted on August 16, 2024 and will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 8,350 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-018441 · form4-06282024_040641.xml · derivative · entry 2 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,350 Underlying: Common Stock · 8,350 shares Expires 2034-06-25 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018441 · form4-06282024_040641.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:08 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-23-037981 · doc4.xml · derivative · entry 1 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders. Read SEC document |
| May 12, 2023 Filed May 15, 2023 17:56 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001209191-23-029594 · doc4.xml · derivative · entry 1 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-05-12 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2023. Read SEC document |
| November 25, 2022 Filed Jan 30, 2023 16:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftCommon Stock | 2,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005476 · doc4.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 F1 · shares: The reported shares were acquired under the Issuer's stock purchase plan on November 20, 2022. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 22:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 9,375 | $0.00 Strike: $13.54 | $0.00 |
DisclosureSEC source: 0001209191-22-051047 · doc4.xml · derivative · entry 2 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 9,375 shares Expires 2032-09-20 F2 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over a one year period following September 21, 2022 (the "Grant Date") such that the option is fully vested on the first anniversary of the Grant Date. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 22:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $13.54 | $0.00 |
DisclosureSEC source: 0001209191-22-051047 · doc4.xml · derivative · entry 1 Kung Winston · CIK 0001666963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-09-20 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over a three year period following September 21, 2022 (the "Grant Date") such that the option is fully vested on the third anniversary of the Grant Date. Read SEC document |
| April 20, 2022 Filed Apr 21, 2022 16:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-22-025171 · doc4.xml · derivative · entry 2 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,034 Underlying: Common Stock · 4,000 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. The underlying shares vest in accordance with the terms of the option grant. Read SEC document |
| April 20, 2022 Filed Apr 21, 2022 16:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 4,000 | $3.22 | $12,880.00 |
DisclosureSEC source: 0001209191-22-025171 · doc4.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 28, 2022 16:18 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 104,400 | $0.00 Strike: $16.29 | $0.00 |
DisclosureSEC source: 0001209191-22-013557 · doc4.xml · derivative · entry 1 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,400 Underlying: Common Stock · 104,400 shares Expires 2032-02-10 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022. Read SEC document |
| December 30, 2021 Filed Feb 8, 2022 16:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftCommon Stock | 2,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007754 · doc4.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,600 F1 · shares: The reported shares were acquired under the Issuer's stock purchase plan on May 20, 2021. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 16:38 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-21-052784 · doc4.xml · derivative · entry 2 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,034 Underlying: Common Stock · 5,000 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. The underlying shares vest in accordance with the terms of the option grant. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 16:38 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 5,000 | $3.22 | $16,100.00 |
DisclosureSEC source: 0001209191-21-052784 · doc4.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 17:39 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-21-049724 · doc4.xml · derivative · entry 3 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,034 Underlying: Common Stock · 4,500 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. The underlying shares vest in accordance with the terms of the option grant. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 17:39 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 4,500 | $33.82 | $152,177.85 |
DisclosureSEC source: 0001209191-21-049724 · doc4.xml · nonDerivative · entry 2 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.75 to $34.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 17:39 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 4,500 | $3.22 | $14,490.00 |
DisclosureSEC source: 0001209191-21-049724 · doc4.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2021 Filed Jul 8, 2021 19:04 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-21-046054 · doc4.xml · derivative · entry 3 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,534 Underlying: Common Stock · 4,500 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. The underlying shares vest in accordance with the terms of the option grant. Read SEC document |
| July 08, 2021 Filed Jul 8, 2021 19:04 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 4,500 | $33.75 | $151,875.00 |
DisclosureSEC source: 0001209191-21-046054 · doc4.xml · nonDerivative · entry 2 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. Read SEC document |
| July 08, 2021 Filed Jul 8, 2021 19:04 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 4,500 | $3.22 | $14,490.00 |
DisclosureSEC source: 0001209191-21-046054 · doc4.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 21:36 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-21-038798 · doc4.xml · derivative · entry 3 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,034 Underlying: Common Stock · 4,500 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. The underlying shares vest in accordance with the terms of the option grant. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 21:36 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 4,500 | $33.75 | $151,875.00 |
DisclosureSEC source: 0001209191-21-038798 · doc4.xml · nonDerivative · entry 2 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 21:36 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 4,500 | $3.22 | $14,490.00 |
DisclosureSEC source: 0001209191-21-038798 · doc4.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2021 Filed Jun 8, 2021 19:17 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 50,337 | $0.00 Strike: $28.33 | $0.00 |
DisclosureSEC source: 0001209191-21-039032 · doc4.xml · derivative · entry 1 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,337 Underlying: Common Stock · 50,337 shares Expires 2031-05-11 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021. Read SEC document |
| May 03, 2021 Filed May 4, 2021 19:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-21-030096 · doc4.xml · derivative · entry 3 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,534 Underlying: Common Stock · 4,500 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. The underlying shares vest in accordance with the terms of the option grant. Read SEC document |
| May 03, 2021 Filed May 4, 2021 19:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 4,500 | $33.75 | $151,875.00 |
DisclosureSEC source: 0001209191-21-030096 · doc4.xml · nonDerivative · entry 2 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020. Read SEC document |
| May 03, 2021 Filed May 4, 2021 19:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 4,500 | $3.22 | $14,490.00 |
DisclosureSEC source: 0001209191-21-030096 · doc4.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2020 Filed Dec 31, 2020 16:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 1,600 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-20-065683 · doc4.xml · derivative · entry 2 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,034 Underlying: Common Stock · 1,600 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Of the 238,634 options held directly by the Reporting Person, 1,600 options were exercised as reported herein and the remaining 237,034 options continue to vest according to the terms of the option grant. F3 · balance_after: The number of shares subject to the option has been reduced by one share, which was inadvertently included in the Reporting Person's Form 3 filed on September 24, 2020. Read SEC document |
| December 08, 2020 Filed Dec 31, 2020 16:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 1,600 | $3.22 | $5,152.00 |
DisclosureSEC source: 0001209191-20-065683 · doc4.xml · nonDerivative · entry 1 Kung Winston · CIK 0001666963 · COO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported shares are subject to the terms of a lock-up agreement, dated June 23, 2020 (the "Lock-Up Agreement"). This report on Form 4 is in accordance with Section (v) of the Lock-Up Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.